• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Fluoxetine Plus CBT for Somatic Symptom Disorder

Fluoxetine Plus CBT for Somatic Symptom Disorder

November 1, 2017
Shirley Tsai
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Shirley Tsai PharmD candidate (2018) Ms. Tsai has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Fallon BA et al, Am J Psychiatry 2017;174(8):756–764

Somatic symptom disorder (formerly known as hypochondriasis) is pretty common, with a prevalence of 5%–7%, and is much more likely to afflict women than men, with a gender ratio of about 10:1. While both psychotherapy and SSRI treatment are helpful, there is limited evidence about the efficacy of combining therapy with medication. A new study sought to remedy this gap.

Researchers recruited 195 people with hypochondriasis (the study occurred before DSM-5) and randomly assigned them to one of four groups: placebo, cognitive behavioral therapy (CBT), fluoxetine, or combination treatment with both CBT and fluoxetine. CBT sessions were delivered from a scripted manual to participants in six 60-minute sessions on a weekly basis, followed by 2 biweekly and then 3 monthly boosters by experienced therapists. Fluoxetine and placebo groups were both given 20- to 30-minute medication management appointments with psychiatrists. Fluoxetine was started at 10 mg QD and gradually increased up to 80 mg QD as tolerated. Patients in the combination group met with both a therapist and psychiatrist. Response was defined as a 25% improvement in symptom severity.

Hypochondriasis symptoms were evaluated at weeks 6, 12, and 24. Based on primary outcome measures at week 24, patients assigned to combination treatment had the highest response rate (47.2%)—higher than the therapy group (39.6%) or the placebo group (29.5%), but not statistically significantly higher than the fluoxetine group (44.4%). However, on a variety of secondary measures, the advantage of combination treatment over fluoxetine alone was less pronounced, and in some cases fluoxetine alone seemed more effective. Interestingly, patients in the fluoxetine-alone group ended up with a mean dose of 40 mg/day; this was higher than patients in the combination group, who took a mean dose of 30.9 mg/day. Adverse events were mild, and were similar in all four treatment groups.

TCPR’s Take
Fluoxetine was effective for symptoms of hypochondriasis. Adding CBT provided only a small additional benefit over fluoxetine alone, although this benefit might have been greater if the dose of fluoxetine in the combination group had been higher. Bottom line, you should consider fluoxetine treatment for your patients with somatic symptom disorder, with or without added CBT.
General Psychiatry
KEYWORDS research_updates
Shirley Tsai

More from this author
www.thecarlatreport.com
Issue Date: November 1, 2017
SUBSCRIBE NOW
Table Of Contents
Closing a Practice: Some Practical Suggestions
Financial Planning for Retirement
Aripiprazole Augmentation May Improve Remission Rates in MDD
Fluoxetine Plus CBT for Somatic Symptom Disorder
CME Post-Test - Retirement, TCPR, November 2017
Note From the Editor-in-Chief
Retirement Toolkits
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.